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Breast lymphoma has been subdivided into primary and
secondary types based on the criteria described by Wise-
man and Liao [1]. Primary breast lymphoma (PBL) is defined
as involvement of the breast localized to one or both
breasts with or without regional lymph nodes involvement,
whereas secondary breast lymphoma refers to systemic
lymph nodes and/or other extranodal organ involvement as
well as involvement of one or both breasts. PBL is rare and
accounts for less than 1% of all patients with non-Hodgkin’s
lymphomas and about 0.1% of all patients with breast
neoplasms [2].
A 63-year-old female complained of a palpable, painless
mass in her right breast for 2 weeks. Physical examination
revealed an elastic hard and mobile round mass in the right
breast. Mammography showed a 4.9 cm  4.1 cm oval,
hyperdense mass with smooth borders at the upper outer
quadrant of the right breast. Ultrasonography revealed
a lobulated mass of 4 cm  2.5 cm with clear margin and
mixed hypo-echoic echotexture. Core needle biopsy
revealed non-Hodgkin’s lymphoma, diffuse, large B cell
type. Immunohistochemical studies showed positive LCA
and CD20. A whole-body 18F-fluorodeoxyglucose positron
emission tomography/computed tomography (18F-FDG-
PET/CT) showed a heterogeneously hyperdense and
intensely FDG-avid mass in the right breast with maximum
standard uptake value (SUV) of 14.4e24.2. There was no
abnormal accumulation at any other site. The patient was
diagnosed as being at clinical stage I lymphoma. After
chemotherapy with six cycles of Mabthera and CHOP
(cyclophosphamide, hydroxyl daunorubicin, oncovin, pred-
nisone), the tumor disappeared and there was no relapse
after 6 months of follow-up.
Most cases of PBL manifest as painless palpable masses
that may mimic carcinoma in 80e100% of patients. Others
showed a mass with local inflammation with or without
palpable lymph nodes [3]. Mammography of PBL presents as
solid masses or diffuse infiltrative type. A hyperdense or
isodense noncalcified solitary lobular mass is the most1607-551X/$36 Copyright ª 2012, Kaohsiung Medical University. Publish
http://dx.doi.org/10.1016/j.kjms.2012.12.008common finding [4]. The margins of the masses are most
commonly irregular or indistinct. Ultrasonography of PBL
has various appearances ranging from well defined to
indistinct, focal to diffuse, and hypo- to hyperechoic [4]. It
most commonly occurs as a solitary hypo-echoic irregular
mass with indistinct margins and hypervascularity on
Doppler imaging. PBL usually demonstrates rapid early
enhancement and washout or plateau kinetics in magnetic
resonance imaging (MRI) [4]. These features are charac-
teristic of malignancy.
Diagnosis of PBL can be made with needle core biopsy.
FDG-PET/CT plays a role in the staging, follow-up and
treatment response of patients with lymphoma. Breast
lymphomatous involvement is characterized by increased
FDG uptake. The degrees of FDG uptake distinguish
aggressive non-Hodgkin’s lymphoma from indolent non-
Hodgkin’s lymphoma [2]. An SUV > 10 suggested more
aggressive disease. Decrement of the SUV of the tumor may
represent a good response to the therapy.
There is still no universal standard treatment of PBL.
Most studies agree that the combination of limited surgery,
anthracycline-based systemic chemotherapy, and radio-
therapy are the best therapeutic options in patients with
PBL [5]. Radical mastectomy may postpone the initiation of
systemic chemotherapy and lead to poorer survival.
Therefore, it should be avoided [5].References
[1] Wiseman C, Liao KT. Primary lymphoma of the breast. Cancer
1972;29:1705e12.
[2] Nguyen NC, Hueser CN, Kaushik A, Farghaly HR, Osman MM. F-
18 fluorodeoxyglucose positron emission tomography and/or
computed tomography findings of an unusual breast lymphoma
case and concurrent cervical cancer: a case report. J Med Case
Reports 2010;4:282.
[3] Seker M, Bilici A, Ustaalioglu BO, Yilmaz B, Ozturk B, Unal A,
et al. Clinicopathologic features of the nine patients with
primary diffuse large B cell lymphoma of the breast. Arch
Gynecol Obstet 2011;284:405e9.ed by Elsevier Taiwan LLC. All rights reserved.
Letter to the Editor 465[4] Meerkotter D, Rubin G, Joske F, Angunawela P, Khalafallah A.
Primary breast lymphoma:a rare entity. Radiol Case 2011;5:1e9.
[5] Yhim HY, Kang HJ, Choi YH, Kim SJ, Kim WS, Chae YS, et al.
Clinical outcomes and prognostic factors in patients with
breast diffuse large B cell lymphoma; Consortium for
Improving Survival of Lymphoma (CISL) study. BMC Cancer
2010;10:321.
En-Hua Huang
Department of Radiology,
Kaohsiung Armed Forces General Hospital,
Kaohsiung, Taiwan
Sheng-Fung Lin
Division of Hema-Oncology,
Department of Internal Medicine, Kaohsiung Medical
University Hospital, Kaohsiung, TaiwanFaculty of Medicine, College of Medicine, Kaohsiung
Medical University, Kaohsiung, Taiwan
Hsin-Ling Yin
Department of Pathology, Kaohsiung Medical University
Hospital, Kaohsiung, Taiwan
Jui-Sheng Hsu*
Department of Medical Imaging, Kaohsiung Medical
University Hospital, Kaohsiung, Taiwan
Graduate Institute of Medicine College of Medicine,
Kaohsiung Medical University, Kaohsiung, Taiwan
*Corresponding author. 100, Tz-You First Road, Kaohsiung
807, Taiwan.
E-mail address: e3124@ms16.hinet.net
